Market Mover: Sutro (STRO) Falls at Midday May 13

Equities Staff  |

Sutro Biopharma Inc (NASDAQ: STRO) shares moved 8.16%, or $0.4 per share, as on 12:09:40 est today. Opening the day at $5.04, 237,964 shares of Sutro exchanged hands and the stock has ranged between $5.15 and $4.49.  

So far this year the company has a YTD change of 67.07%.

Sutro expects its next earnings on 2022-08-09.

For technical charts, analysis, and more on Sutro visit the company profile.

About Sutro Biopharma Inc

Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

To get more information on Sutro Biopharma Inc and to follow the company's latest updates, you can visit the company's profile page here: Sutro Biopharma Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold
The Best Laid Plans of Mice and Men — Part I
Bumble Beats First Quarter Estimates, Has Over 3 Million Paying Users
Squarespace Beats Revenue Estimates With Record Q1
BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million
How To Trade in a Bearish Market
AbbVie and Teva Weighing $5 Billion Opioid Lawsuit Settlement



Market Movers

Sponsored Financial Content